New anti-hepatitis B drug to make debut in December

Published: 2006-08-02 07:00:00

Updated: 2006-08-02 07:00:00

The Korea Food and Drug Administration (KFDA) approved a local pharmaceutical company's anti-hepatitis B drug on July 28 and the market for anti-hepatits B medicines dominated by imported drugs is expected to enter fierce competition.

We have approved Bukwang Pharm's Levovir capsule (clevudine), a hepatitis B medicine. And the drug is the first of its kind developed by the Korean company,'' ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.